| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12072-017-9841-Y |
| P8608 | Fatcat ID | release_b74yyojngjbrjbkkcaj3frtyb4 |
| P698 | PubMed publication ID | 29330836 |
| P2093 | author name string | Ping Chen | |
| Chao Huang | |||
| Bing Chen | |||
| Qi Gao | |||
| Qihui Luo | |||
| Wentao Liu | |||
| Zhengli Chen | |||
| Wen Zeng | |||
| Jingfei Chen | |||
| Like Li | |||
| P2860 | cites work | Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 |
| Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity | Q29614932 | ||
| The natural history of nonalcoholic fatty liver disease: a population-based cohort study | Q29617161 | ||
| TGF-beta signaling and the fibrotic response | Q29620099 | ||
| Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. | Q33762356 | ||
| Origin and function of myofibroblasts in kidney fibrosis | Q33792700 | ||
| Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis | Q35086389 | ||
| Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. | Q36075087 | ||
| The epidemiology of nonalcoholic fatty liver disease in adults | Q36422726 | ||
| Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease | Q37067362 | ||
| The Hippo pathway and human cancer. | Q38087215 | ||
| Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
| Crosstalk between Hippo and TGFβ: Subcellular Localization of YAP/TAZ/Smad Complexes | Q38879467 | ||
| YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis. | Q39933604 | ||
| Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation | Q40728276 | ||
| Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 | ||
| Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats | Q44507331 | ||
| Prevalence of and risk factors for fatty liver in a general population of Shanghai, China | Q46591774 | ||
| Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. | Q53540807 | ||
| The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. | Q54275915 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q84235401 | ||
| P921 | main subject | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| non-alcoholic fatty liver | Q66299798 | ||
| P577 | publication date | 2018-01-12 | |
| P1433 | published in | Hepatology international | Q26842730 |
| P1476 | title | Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. |
| Q90010946 | Anti-inflammatory and hepatoprotective effects of exopolysaccharides isolated from Pleurotus geesteranus on alcohol-induced liver injury |
| Q90310135 | Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway |
| Q89919275 | Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease |
| Q91833695 | TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma |
| Q96576943 | Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine |
Search more.